MedTrace Logo

High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone

NCT00809068 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-02-02

No results posted yet for this study

Summary

Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%.

This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone.

Conditions

  • HDL Cholesterol

Interventions

DRUG

fenofibrate and tibolone

fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks

DRUG

tibolone

tibolone 2.5 mg daily 23 weeks

Sponsors & Collaborators

  • Keogh Institute for Medical Research

    lead OTHER

Principal Investigators

  • Bronwyn G Stuckey, MBBS FRACP · Keogh Institute for Medical Research

  • Gerald F Watts, MD PhD FRACP · School pf Medicine and Pharmacology, Royal Perth Hospital.

  • Rosalind Hampton, BSc MBBS · Keogh Institute for Medical Research

  • Hugh Barrett, BAgSc PhD · School of Medicine and Pharmacology, Royal Perth Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-08-31
Completion
2009-10-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00809068 on ClinicalTrials.gov